Madrigal Pharmaceuticals Inc (MDGL) - News Archive

Madrigal Pharmaceuticals Strengthens Leadership Team Amid Financial ChallengesIntroductionMadrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a biopharmaceutical company renowned for its focus on developing novel therapeutic...

Rezdiffra (resmetirom) Shows Promising Health-Related Quality of Life Improvements in Phase 3 MAESTRO-NASH Trial Madrigal Pharmaceuticals announces the publication of promising health-related quality of life results fro...

Madrigal Pharmaceuticals, a prominent biopharmaceutical company striving to develop innovative treatments for nonalcoholic steatohepatitis (NASH), has recently announced the appointment of Shannon Kelley as their new Ge...

Nonalcoholic steatohepatitis (NASH) is an increasingly prevalent liver disease characterized by inflammation and liver cell damage, which can progress to fibrosis, cirrhosis, and ultimately, liver failure. There is a cl...

Madrigal Pharmaceuticals Announces Upsized $600 Million Public Offering and Record Net LossCONSHOHOCKEN, Pa., March 18, 2024 - Madrigal Pharmaceuticals, Inc. (Nasdaq: MDGL), a leading biopharmaceutical company specializ...

Madrigal Pharmaceuticals Embarks on $500 Million Public Offering to Fuel Innovation in NASH TherapeuticsCONSHOHOCKEN, Pa., March 18, 2024 - Madrigal Pharmaceuticals, a leading biopharmaceutical company focused on ground...

Nonalcoholic steatohepatitis (NASH) is a progressive liver disease characterized by inflammation and fat accumulation in the liver, leading to liver fibrosis and potentially cirrhosis. The absence of effective pharmacol...

Madrigal Pharmaceuticals, a renowned clinical-stage biopharmaceutical company focusing on innovative treatments for nonalcoholic steatohepatitis (NASH), made a significant announcement today regarding equity awards gran...

Nonalcoholic steatohepatitis (NASH) and metabolic dysfunction-associated steatohepatitis (MASH) with liver fibrosis have become significant global health concerns. With limited available treatment options, patients suff...

Madrigal Pharmaceuticals Announces Promising Results for Resmetirom in Phase 3 Trial for NASH TreatmentCONSHOHOCKEN, Pa., Feb. 08, 2024 - Madrigal Pharmaceuticals, a leading clinical-stage biopharmaceutical company dedi...

In an official press release today, Madrigal Pharmaceuticals, a renowned clinical-stage biopharmaceutical company focusing on groundbreaking therapies for nonalcoholic steatohepatitis (NASH), announced the issuance of e...

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) has recently welcomed three key additions to its leadership team, aiming to bolster its pursuit of innovative therapeutics for nonalcoholic steatohepatitis (NASH). The compan...

Madrigal Pharmaceuticals Presents Five Health Economics Outcomes Research s at the NASH-TAG Annual ConferenceCONSHOHOCKEN, Pa., Jan. 04, 2024 - Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceu...

Madrigal Pharmaceuticals Grants Inducement Awards to New Employees, Expands Inducement PlanCONSHOHOCKEN, Pa., Dec. 22, 2023 - Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company spec...

CONSHOHOCKEN, Pa., Oct. 12, 2023 - Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL), a clinical-stage biopharmaceutical company dedicated to developing innovative therapies for nonalcoholic steatohepatitis (NASH), announced...